Tumor Necrosis Factor Alpha Inhibitors Market Research Report–Forecast till 2023

Market Scenario:
The tumor necrosis factor alpha (TNF-α) inhibitors represent one of the major treatment methods for inflammatory diseases. Globally, this drug class is known to be the most successful drugs in the overall pharmaceutical industry. Several conditions such as inflammations, rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and seronegative spondyloarthropathies, can be treated with the help of these drugs. The total sales of the top three blockbuster TNF-alpha inhibitors namely Remicade, Enbrel, and Humira had surpassed USD 32 billion in 2016.

Xalud’s lead product XT-150 harnesses the power of the body’s potent anti-inflammatory protein IL-10 to treat inflammatory diseases of the central nervous system (CNS) and joints. XT-150 is in the stage of the preclinical trials for multiple sclerosis, neuropathic pain, and osteoarthritis. In leading rodent model study for neuropathic pain XT-150 has been highly efficacious. Single injection delivers it into the fluid surrounding the spinal cord ensuring that the therapy reaches its target.

In the present scenario, developing countries have stringent regulatory requirements for approval of a new drug. It is a difficult task for marketing authorization application to get single regulatory for a new drug product which belongs to various categories of drugs such as NCE, biologicals, controlled drugs, etc. Therefore, the knowledge of precise and detailed regulatory requirements for market authorization application of different categories of drugs should be known to establish a suitable regulatory strategy. There is a need for pronounce and a fine balance between the persistence of gaining market access to pharmaceuticals, to protect the public health and facilitate healthy growth of pharmaceutical manufacturers.

The global tumor necrosis factor alpha inhibitors market is expected to grow at a CAGR of approximately 7.1% during the forecast period 2017-2023.

Intended Audience

- Tumor Necrosis Factor Alpha Inhibitors Drug Suppliers
- Tumor Necrosis Factor Alpha Inhibitors Drug Manufacturers
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Academic Medical Institutes and Universities
- Research Methodology

Sources: Annual reports, Press release, White paper, and Company presentation
Segmentation

The global tumor necrosis factor alpha inhibitors market is segmented on the basis of the drug, disorder type, route of administration, stage of clinical trials, and application.

On the basis of the drug, the global tumor necrosis factor alpha inhibitors market is segmented into Humira, Enbrel, Remicade, and others.

On the basis of the disease type, the global tumor necrosis factor alpha inhibitors market is segmented into Alzheimer’s diseases, Parkinson’s diseases, ischemic stroke, multiple sclerosis, and others.

By the route of administration, the global tumor necrosis factor alpha inhibitors market is segmented into oral, subcutaneous, intravenous, and others.

On the basis of the stage of clinical trials, the global tumor necrosis factor alpha inhibitors market is segmented into the preclinical trial, phase 1 clinical trial, phase 2 clinical trial, phase 3 clinical trial, and phase 4 clinical trial.

On the basis of the application, the global tumor necrosis factor alpha inhibitors market is segmented into medicine, scientific research, and others.

Regional Analysis

The global tumor necrosis factor alpha inhibitors market is segmented as the Americas, Europe, Asia Pacific and the Middle East and Africa.

The Americas is projected to hold the largest share of the global tumor necrosis factor alpha inhibitors market. P2D Biosciences, a US-based company, received $2.3 million funding from NIH (National Institutes of Health) with four grants. The grants include the development of new drugs for the treatment of acute leukemia and Alzheimer’s disease and a new drug to improve stem cell transplant therapy for treating leukemia and lymphomas, which will help P2D to develop medical advances that improve the lives and health of people who are affected with these diseases.

Europe is expected to capture the second lead in this market in the coming five years owing to substantial technological advancements. In 2016, LEO Pharma, a Denmark based company entered biologics through a strategic partnership with AstraZeneca. The partnership will help LEO Pharma enhance their product portfolio. A strategic alliance with a healthcare giant will help LEO pharma expand their geographic presence and become a world leader in dermatology segment.
Moreover, Asia Pacific is expected to witness the fastest growth rate over the forecast period. The Middle East and Africa are also expected to show healthy growth in the coming five years.

Key Players

In May 2016, Pfizer acquires Anacor for its inflammatory & immunology portfolio. Anacor is a biopharmaceutical company focused on small molecule therapeutics from its boron chemistry platform, and its asset Crisaborole is in FDA review if approved will be a first-line treatment option for patients with atopic dermatitis. They have entered into a definitive merger agreement under which Pfizer will acquire Anacor for approximately $5.2 billion which assumes the conversion of Anacor’s outstanding convertible notes. Anacor will be a strong fit with Pfizer’s innovative business due to the strategic focus on inflammation and immunology and is expected to enhance near-term revenue growth for the innovative business.

Some of key the players in the global tumor necrosis factor alpha inhibitors market are AbbVie Inc. (U.S.), Ablynx (Belgium), Apogenix GmbH (Germany), ArroyGen Biopharma (U.S.), Bionovis (Brazil), CASI Pharmaceuticals (U.S.), Celltrion Healthcare (South Korea.), Celgene Corporation (U.S.), Delenex Therapeutics (Switzerland), Dexa Medica (Indonesia), EPIRUS Biopharmaceuticals (U.S.), Janssen Biotech (U.S.), GlaxoSmithKline Inc. (U.S.), HanAll Biopharma (South Korea.), Intas Pharmaceuticals (India), LEO Pharma (Denmark), LG Life Sciences (U.S.), MedImmune (U.S.), Momenta Pharmaceuticals (U.S.), Novartis AG (Switzerland), Sanofi-Aventis (France), Zydus Cadila (India), and others.

Contents:

TABLE OF CONTENT

Chapter 1. Report Prologue
Chapter 2. Market Introduction
  2.1 Definition
  2.2 Scope of the Study
  2.2.1 Research Objective
  2.2.2 Assumptions
  2.2.3 Limitations
Chapter 3. Research Methodology
  3.1 Introduction
  3.2 Primary Research
  3.3 Secondary research
  3.4 Market Size Estimation
Chapter 4. Market Dynamics
  4.1 Drivers
  4.2 Restrains
  4.3 Opportunities
  4.4 Challenges
  4.5 Macroeconomic Indicators
  4.6 Stage of clinical trials Trends & Assessment
Chapter 5. Market Factor Analysis
  5.1 Porter’s Five Forces Analysis
    5.1.1 Bargaining Power of Suppliers
    5.1.2 Bargaining Power of Buyers
    5.1.3 Threat of New Entrants
    5.1.4 Threat of Substitutes
    5.1.5 Intensity of Rivalry
  5.2 Value Chain Analysis
  5.3 Investment Feasibility Analysis
Chapter 6. Global Tumor Necrosis Factor Alpha Inhibitors Market, by Drug

6.1 Introduction

6.2 Humira

6.2.1 Market Estimates & Forecast, 2016 – 2023

6.3 Enbrel

6.3.1 Market Estimates & Forecast, 2016 – 2023

6.4 Remicade

6.4.1 Market Estimates & Forecast, 2016 – 2023

6.5 Others

Chapter 7. Global Tumor Necrosis Factor Alpha Inhibitors Market, by Disease type

7.1 Introduction

7.2 Alzheimer's diseases

7.2.1 Market Estimates & Forecast, 2017 – 2023

7.3 Parkinson's diseases

7.3.1 Market Estimates & Forecast, 2017 – 2023

7.4 Ischemic stroke

7.4.1 Market Estimates & Forecast, 2017 – 2023

7.5 Multiple sclerosis

7.5.1 Market Estimates & Forecast, 2017 – 2023

7.6 Others

Chapter 8. Global Tumor Necrosis Factor Alpha Inhibitors Market, by Route of administration

8.1 Introduction

8.2 Oral

8.2.1 Market Estimates & Forecast, 2017 – 2023

8.3 Subcutaneous

8.3.1 Market Estimates & Forecast, 2017 – 2023

8.4 Intravenous

8.4.1 Market Estimates & Forecast, 2017 – 2023

8.5 Others

Chapter 9. Global Tumor Necrosis Factor Alpha Inhibitors Market, by Stage of clinical trials

9.1 Introduction

9.2 Preclinical trial

9.2.1 Market Estimates & Forecast, 2017 – 2023

9.3 Phase 1 clinical trial

9.3.1 Market Estimates & Forecast, 2017 – 2023

9.4 Phase 2 clinical trial

9.4.1 Market Estimates & Forecast, 2017 – 2023

9.5 Phase 3 clinical trial

9.5.1 Market Estimates & Forecast, 2017 – 2023

9.6 Phase 4 clinical trial


Chapter 10. Global Tumor Necrosis Factor Alpha Inhibitors Market, by Application

10.1 Introduction

10.2 Medicine

10.2.1 Market Estimates & Forecast, 2017 – 2023

10.3 Scientific research

10.3.1 Market Estimates & Forecast, 2017 – 2023
Chapter 11 Global Tumor Necrosis Factor Alpha Inhibitors Market, by Region

11.1 Introduction
11.2 Americas
11.2.1 North America
11.2.1.1 U.S.
11.2.1.2 Canada
11.2.2 South America
11.3 Europe
11.3.1 Western Europe
11.3.1.1 Germany
11.3.1.2 France
11.3.1.3 Italy
11.3.1.4 Spain
11.3.1.5 U.K
11.3.1.6 Rest of Western Europe
11.3.2 Eastern Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 Republic of Korea
11.4.6 Rest of Asia Pacific
11.5 The Middle East & Africa
11.5.1 United Arab Emirates
11.5.2 Saudi Arabia
11.5.3 Rest of the Middle East & Africa

Chapter 12 Company Landscape

12.1 Introduction
12.2 Market Share Analysis
12.3 Key Development & Strategies
12.3.1 Key Developments

Chapter 13 Company Profiles

13.1 AbbVie Inc.
13.1.1 Company Overview
13.1.2 Route of administration Overview
13.1.3 Financials
13.1.4 SWOT Analysis
13.2 Ablynx
13.2.1 Company Overview
13.2.2 Route of administration Overview
13.2.3 Financial Overview
13.2.4 Key Developments
13.2.5 SWOT Analysis
13.3 Apogenix GmBH
13.3.1 Company Overview
13.3.2 Route of administration Overview
13.3.3 Financial Overview
13.3.4 Key Development
13.3.5 SWOT Analysis
13.4 Celgene Corporation
13.4.1 Company Overview
13.4.2 Route of administration/Business Segment Overview
13.4.3 Financial Overview
13.4.4 Key Development
13.4.5 SWOT Analysis
13.5 GlaxoSmithKline Inc.
13.5.1 Company Overview
13.5.2 Route of administration Overview
13.5.3 Financial overview
13.5.4 Key Developments
13.6 Novartis AG
13.6.1 Company Overview
13.6.2 Route of administration Overview
13.6.3 Financial Overview
13.6.4 Key Developments
13.7 Sanofi-Aventis
13.7.1 Overview
13.7.2 Route of administration Overview
13.7.3 Financials
13.7.4 Key Developments
13.7.5 SWOT Analysis
13.8 Zydus Cadila
13.8.1 Company Overview
13.8.2 Route of administration/Business Segment Overview
13.8.3 Financial Overview
13.8.4 Key Development
13.8.5 SWOT Analysis
13.9 Delenex Therapeutics
13.9.1 Company Overview
13.9.2 Route of administration Overview
13.9.3 Financial overview
13.9.4 Key Developments
13.10 Others

Chapter 14 MRFR Conclusion
14.1 Key Findings
14.1.1 From CEO's View Point
14.1.2 Unmet Needs of the Market
14.2 Key Companies to Watch
14.3 Prediction of Pharmaceutical industry

Chapter 15 Appendix

LIST OF TABLES

Table 1 Tumor Necrosis Factor Alpha Inhibitors Industry Synopsis, 2017 – 2023
Table 2 Tumor Necrosis Factor Alpha Inhibitors Market Estimates and Forecast, 2017 – 2023, (USD Million)
Figure 35 Sanofi-Aventis: Key Financials
Figure 36 Sanofi-Aventis: Segmental Revenue
Figure 37 Sanofi-Aventis: Geographical Revenue
Figure 38 Zydus Cadila: Key Financials
Figure 39 Zydus Cadila: Segmental Revenue
Figure 40 Zydus Cadila: Geographical Revenue
Figure 41 Delenex Therapeutics: Key Financials
Figure 42 Delenex Therapeutics: Segmental Revenue
Figure 43 Delenex Therapeutics: Geographical Revenue